38696-23-0 Usage
Uses
Used in Pharmaceutical Industry:
5-Bromo-2-methoxy-4-methylpyrimidine is used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into various drug molecules, contributing to the development of new medications.
Used in Agrochemical Industry:
5-BroMo-2-Methoxy-4-MethylpyriMidine is also utilized as an intermediate in the synthesis of agrochemicals, playing a role in the creation of pesticides and other agricultural products to improve crop protection and yield.
Used in Research Activities:
5-Bromo-2-methoxy-4-methylpyrimidine serves as a building block in organic synthesis within research settings, enabling scientists to explore and create new chemical compounds for various applications.
Used in Material Development:
5-BroMo-2-Methoxy-4-MethylpyriMidine has potential applications in the development of new materials and compounds for different industrial purposes, showcasing its versatility and utility across a range of sectors.
Check Digit Verification of cas no
The CAS Registry Mumber 38696-23-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,8,6,9 and 6 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 38696-23:
(7*3)+(6*8)+(5*6)+(4*9)+(3*6)+(2*2)+(1*3)=160
160 % 10 = 0
So 38696-23-0 is a valid CAS Registry Number.
38696-23-0Relevant academic research and scientific papers
IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER
-
Paragraph 0288, (2020/12/29)
Disclosed are compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, disclosed are compounds of Formula (I) and pharmaceutical compositions thereof, and methods of using the compounds and pharmaceutical compositions in, for example, methods of treating cancer.
NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS
-
Paragraph 0347, (2020/11/03)
Disclosed are compounds of formula (I) or (II) that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
PRC2 INHIBITORS
-
Paragraph 0297, (2019/08/26)
The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention. (Formula (I))
